Last reviewed · How we verify
PILOCARPINE HYDROCHLORIDE
At a glance
| Generic name | PILOCARPINE HYDROCHLORIDE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1984 |
Approved indications
Common side effects
- Sweating
- Sweating
- Urinary Frequency
- Urinary Frequency
- Chills
- Chills
- Flushing
- Flushing
- Nausea
- Nausea
- Diarrhea
- Diarrhea
Serious adverse events
- Myocardial Infarction
- Syncope
- Glaucoma
- Bradycardia
- Esophagitis
- Leukopenia
- Stridor
- Dysphagia
- Tachycardia
- Hypertension
Key clinical trials
- Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia (PHASE3)
- Novel Point-of-care Sweat Chloride Testing Device for Monitoring CFTR Function (NA)
- Pilocarpine Use After Kahook Goniotomy (PHASE3)
- Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia (PHASE2)
- Optimal Treatment Protocol for Selective Laser Trabeculoplasty (NA)
- Optimal Treatment Protocol for Selective Laser Trabeculoplasty - Repeat Trial (NA)
- Evaluation of NV701 (Pilocarpine 1.25%) Compared With Vuity (Pilocarpine 1.25%) on Pupil Size in Subjects With Presbyopia (EARLY_PHASE1)
- Quality of Life in Presbyopic Patients Who Are Treated With Qlosi (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PILOCARPINE HYDROCHLORIDE CI brief — competitive landscape report
- PILOCARPINE HYDROCHLORIDE updates RSS · CI watch RSS